Twist Bioscience Bundle
How Did Twist Bioscience Revolutionize Synthetic Biology?
Twist Bioscience, a frontrunner in synthetic biology, has fundamentally changed how we approach DNA manufacturing. Their innovative silicon-based platform has enabled the creation of high-quality Twist Bioscience SWOT Analysis synthetic DNA at an unprecedented scale, impacting multiple sectors. This groundbreaking technology, born from a vision in 2013, aimed to industrialize DNA synthesis, a goal that has reshaped the landscape of genetic engineering.
From its inception, Twist Bioscience has been at the forefront of gene synthesis, offering cutting-edge solutions for researchers and businesses. The company's focus on next-generation sequencing and oligonucleotides has fueled its growth, positioning it as a key player in the genomics field. This brief history of Twist Bioscience company highlights its journey from a startup to a leading provider of synthetic biology solutions, driven by its commitment to innovation and strategic partnerships. The company's impact on drug discovery and other applications continues to expand.
What is the Twist Bioscience Founding Story?
The story of Twist Bioscience began in 2013, with Emily Leproust, Bill Banyai, and Bill Peck at the helm. Emily Leproust, the current CEO, brought expertise in organic chemistry and an entrepreneurial drive, influenced by her family's business background. The founders saw a chance to revolutionize DNA production, moving beyond conventional methods to a high-throughput, semiconductor-based synthesis technology.
Their goal was to create a scalable platform to synthesize DNA accurately and efficiently, believing it could change the world. This vision led to the development of the Twist Biosynthesis Platform. The company's early funding came from seed rounds, eventually raising a total of $321 million over 11 rounds from investors like Fidelity Investments and Illumina.
A key early collaboration was with Ginkgo Bioworks in 2015, where Twist produced over 100 million bases of synthetic DNA, representing 10% of the synthetic DNA market that year. Soon after, Twist partnered with Microsoft to explore using synthetic DNA for digital data storage, showcasing its technology's versatility. These early partnerships and the ability to scale DNA production by a factor of 1,000x, using micro-wells on a silicon chip, were crucial in establishing Twist Bioscience's foundational expertise and market relevance. To learn more about the company's strategic growth, consider reading the Growth Strategy of Twist Bioscience.
Key Highlights of Twist Bioscience's Founding
Twist Bioscience was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
- The initial vision was to transform DNA production using a semiconductor-based synthesis technology.
- The Twist Biosynthesis Platform launched in 2015, offering custom DNA sequences.
- Early funding included $321 million raised over 11 rounds.
- Collaborations with Ginkgo Bioworks and Microsoft highlighted the technology's potential.
Twist Bioscience SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Twist Bioscience?
The early growth of Twist Bioscience was marked by significant technological advancements and strategic market penetration. Founded in 2013, the company quickly established itself in the field of DNA synthesis, launching its initial product in 2015. This platform enabled researchers to order custom DNA sequences online, making gene synthesis more accessible and industrializing the engineering of biology.
Technological Advancements and Funding
Twist Bioscience experienced substantial team expansion and secured significant capital raises to fuel its growth. In 2017, the company raised $61 million in a Series D funding round, which facilitated the expansion of operations and accelerated new technology development. By 2018, Twist had expanded globally and was generating over $25 million in revenue, supporting diverse applications.
Market Expansion and Revenue Growth
The company continued to expand its market presence and product offerings. In fiscal year 2024, Twist Bioscience reported total revenue of $313 million, a 28% year-over-year increase. SynBio revenue grew to $123.5 million (26% increase year-over-year), and NGS revenue reached $169.1 million (37% growth year-over-year). The customer base expanded to over 3,500 by the end of 2024.
Recent Financial Performance
In the second quarter of fiscal 2025, ended March 31, 2025, Twist Bioscience reported record revenue of $92.8 million, up 23% year-over-year. SynBio revenue grew 21% to $36.0 million, and NGS revenue increased 25% to $51.1 million. The company achieved a gross margin of 49.6% in Q2 FY2025, up from 41.0% in the same period of fiscal 2024.
Strategic Initiatives and Customer Growth
Twist Bioscience has shipped products to approximately 2,431 customers in Q2 FY2025, compared to approximately 2,253 customers in Q2 FY2024. The company's strategic focus on operational efficiency and market diversification, including expansion into new geographic regions, has significantly shaped its trajectory. For more information on the competitive landscape, see Competitors Landscape of Twist Bioscience.
Twist Bioscience PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Twist Bioscience history?
The history of Twist Bioscience is marked by significant achievements in the field of synthetic biology and genomics. The company's journey began with the development of its innovative silicon-based DNA synthesis platform, which has been the cornerstone of its operations, enabling high-throughput and cost-effective production of synthetic DNA.
| Year | Milestone |
|---|---|
| 2015 | Launched the Twist Biosynthesis Platform, streamlining DNA synthesis for researchers. |
| 2025 | Granted a patent in April for 'Methods for seamless nucleic acid assembly'. |
| 2025 | Spun out its DNA data storage application into an independent company, Atlas Data Storage, in May. |
Key innovations at Twist Bioscience include continuous enhancements to its Express portfolio, offering faster delivery times for high-quality DNA, which has expanded its customer base. The company has also focused on securing numerous patents in molecular biology, biotechnology, and genetics, underscoring its commitment to technological advancement.
Silicon-Based DNA Synthesis Platform
This platform allows for high-throughput, cost-effective, and accurate manufacturing of synthetic DNA, which is foundational to its product offerings. This innovation has been critical in enabling the company to produce synthetic genes, oligonucleotides, and NGS target enrichment solutions.
Express Portfolio Enhancements
The Express portfolio has been continuously enhanced to offer faster delivery times for high-quality DNA, expanding the customer base and increasing wallet share. This focus on efficiency and speed has been a key factor in maintaining a competitive edge in the market.
Strategic Partnerships
Partnerships, such as the ongoing collaboration with Ginkgo Bioworks, are crucial for expanding product offerings and market reach. The collaboration with Curio Genomics aims to accelerate NGS workflows in agrigenomics, demonstrating the company's commitment to diverse applications.
Patent Portfolio
Twist Bioscience has secured numerous patents in molecular biology, biotechnology, and genetics. A patent granted in April 2025 for 'Methods for seamless nucleic acid assembly' highlights the company's ongoing innovation in the field.
Focus on Operational Efficiencies
Twist is focused on operational efficiencies and gross margin expansion, aiming for a 50% gross margin by Q4 2025. The Q2 FY2025 gross margin reached 49.6%, demonstrating progress towards this goal.
Spin-off of DNA Data Storage
In May 2025, Twist Bioscience spun out its DNA data storage application into an independent company, Atlas Data Storage, with significant funding. This strategic move allows Twist to focus on its core life sciences business and accelerate its journey toward profitability, with an expectation to achieve adjusted EBITDA breakeven by the end of fiscal 2026.
Despite its achievements, Twist Bioscience has faced challenges, including the need to adapt to the rapidly evolving field of synthetic biology and the goal of achieving GAAP profitability. The company reported a net loss of $39.3 million in Q2 FY2025, though this was an improvement from $45.5 million in Q2 FY2024. Funding challenges, particularly in a landscape of rising interest rates, have also impacted the genomics and biotech industries, including Twist Bioscience.
GAAP Profitability
The company has faced challenges in consistently achieving GAAP profitability. Efforts to improve financial performance include operational efficiencies and gross margin expansion, targeting a 50% gross margin by Q4 2025.
Financial Performance
Twist Bioscience reported a net loss of $39.3 million in Q2 FY2025, an improvement from $45.5 million in Q2 FY2024. The company's investment in DNA data storage was strategically reduced by 50% from $50 million to $25 million to conserve capital.
Market Dynamics and Strategic Adjustments
In response to market dynamics, Twist has focused on operational efficiencies and gross margin expansion. The company is aiming for a 50% gross margin by Q4 2025, with Q2 FY2025 gross margin reaching 49.6%.
Resource Allocation
The company's investment in DNA data storage was strategically reduced by 50% from $50 million to $25 million to conserve capital. This indicates a pivot in resource allocation, focusing on core business areas.
Spin-off of DNA Data Storage
The spin-off of the DNA data storage application into Atlas Data Storage allows Twist to focus on its core life sciences business. This strategic move is expected to accelerate the journey toward profitability, with an expectation to achieve adjusted EBITDA breakeven by the end of fiscal 2026.
Industry Trends
These experiences have reinforced the company's commitment to innovation and operational discipline, connecting its achievements and challenges to broader industry trends in synthetic biology and genomics. The company's focus on innovation and operational discipline is crucial.
Twist Bioscience Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Twist Bioscience?
Founded in 2013, Twist Bioscience quickly established itself as a leader in the DNA synthesis market. The company's journey has been marked by significant milestones, from the launch of its synthetic DNA platform to its public listing and strategic partnerships. Focusing on innovation and expansion, Twist Bioscience continues to evolve, with a strong emphasis on financial growth and technological advancements.
| Year | Key Event |
|---|---|
| 2013 | Twist Bioscience was founded by Emily Leproust, Bill Banyai, and Bill Peck in South San Francisco, California. |
| 2015 | Launched the Twist Biosynthesis Platform and partnered with Ginkgo Bioworks and Microsoft. |
| 2017 | Raised $61 million in a Series D funding round. |
| 2018 | Expanded globally and reported over $25 million in revenue. |
| 2019 | Went public on the NASDAQ stock exchange under the ticker symbol TWST. |
| 2021 | Launched a new CAD platform for whole genome design in collaboration with Genome Project-Write. |
| 2024 | Reported total revenue of $313 million, a 28% year-over-year increase. |
| 2025 (Q1 FY25, ended Dec 31, 2024) | Reported record revenue of $88.7 million, a 24% increase year-over-year, and a gross margin of 48.3%. |
| 2025 (March) | Presented at the Barclays 27th Annual Global Healthcare Conference. |
| 2025 (May 5) | Announced fiscal Q2 2025 financial results, reporting record revenue of $92.8 million and a gross margin of 49.6%. Spun out its DNA data storage application as an independent company, Atlas Data Storage, with $155 million in funding. |
| 2025 (May 8) | Revised collaboration agreement with Ginkgo Bioworks, including long DNA IP for Twist. |
| 2025 (May 22) | Expanded collaboration with Element Biosciences to transform Next Generation Sequencing workflows. |
| 2025 (June 3) | Presented at the 45th Annual William Blair Growth Stock Conference. |
Financial Targets for 2025
For the full fiscal year 2025, the company anticipates total revenues between $372 million and $379 million, indicating approximately 20% year-over-year growth. They are aiming for a gross margin exceeding 50% by Q4 fiscal 2025. These targets reflect the company's commitment to sustained financial performance.
Strategic Initiatives
The spin-out of Atlas Data Storage is expected to positively impact adjusted EBITDA by $5 million per quarter starting in Q4 FY2025. This strategic move is designed to accelerate the timeline towards adjusted EBITDA breakeven by the end of fiscal 2026. The focus remains on enhancing the DNA synthesis platform.
Market Expansion and Capacity
Twist plans to expand its customer base, especially in the liquid biopsy and MRD markets. Their 'factory of the future' currently operates at less than 50% capacity, with a potential capacity of over $700 million. This indicates significant room for scaling production and meeting growing demand for oligonucleotides.
Analyst Predictions
Analyst predictions for the company's stock in June 2025 suggest a potential increase, with a forecasted value around $30.07 per share. The forward-looking strategy emphasizes a balanced approach to growth and profitability, with ongoing focus on operational efficiency and prudent investments. This reflects confidence in the company's future.
Twist Bioscience Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of Twist Bioscience Company?
- What is Growth Strategy and Future Prospects of Twist Bioscience Company?
- How Does Twist Bioscience Company Work?
- What is Sales and Marketing Strategy of Twist Bioscience Company?
- What is Brief History of Twist Bioscience Company?
- Who Owns Twist Bioscience Company?
- What is Customer Demographics and Target Market of Twist Bioscience Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.